{
    "Trade/Device Name(s)": [
        "ARK Hydrocodone Assay"
    ],
    "Submitter Information": "ARK Diagnostics, Inc.",
    "510(k) Number": "K231752",
    "Predicate Device Reference 510(k) Number(s)": [
        "K150502"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "October 6, 2023",
    "Summary Letter Received Date": "October 6, 2023",
    "Submission Date": "June 5, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Hydrocodone",
        "Hydromorphone",
        "Norhydrocodone"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Beckman Coulter AU680 automated clinical chemistry analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for ARK Hydrocodone Assay, a homogeneous enzyme immunoassay for qualitative and semi-quantitative detection of hydrocodone and its metabolites in human urine.",
    "Indications for Use Summary": "Intended for qualitative detection and/or semi-quantitative estimation of hydrocodone and its metabolites in human urine at a cutoff of 300 ng/mL, supporting specimen dilution for confirmatory testing and establishment of laboratory quality control procedures.",
    "fda_folder": "Toxicology"
}